# EDGAR Filing Document

**Accession Number:** 0001507650
**File Stem:** 0001599298-25-000107
**Filing Date:** 2025-6
**Character Count:** 7188
**Document Hash:** 48e09dd560733566280fef2b068ccd17
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001599298-25-000107.hdr.sgml**: 20250602

**ACCESSION NUMBER**: 0001599298-25-000107

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250530

**FILED AS OF DATE**: 20250602

**DATE AS OF CHANGE**: 20250602

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Zanganeh Mahkam
- **CENTRAL INDEX KEY:** 0001507650

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36866
- **FILM NUMBER:** 251015930

**MAIL ADDRESS:**
- **STREET 1:** 51 ADAM WAY
- **CITY:** ATHERTON
- **STATE:** CA
- **ZIP:** 94027

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Zanganeh Maky
- **DATE OF NAME CHANGE:** 20101210
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Summit Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001599298
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 371979717
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 601 BRICKELL KEY DRIVE
- **STREET 2:** SUITE 1000
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33131
- **BUSINESS PHONE:** 305-203-2034

**MAIL ADDRESS:**
- **STREET 1:** 601 BRICKELL KEY DRIVE
- **STREET 2:** SUITE 1000
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33131

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Summit Therapeutics plc
- **DATE OF NAME CHANGE:** 20150219

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Summit Corp plc
- **DATE OF NAME CHANGE:** 20140205

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Zanganeh Mahkam<br><sub>(Last) (First) (Middle)</sub><br>C/O SUMMIT THERAPEUTICS INC.<br>601 BRICKELL KEY DRIVE, SUITE 1000<br><sub>(Street)</sub><br>MIAMI, FL 33131<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-05-30 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Co-Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Summit Therapeutics Inc. [ SMMT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-05-30 |  | M<sup>(1)</sup> |  | 74545 | A | $2.64 | 555754696<sup>(2)</sup> | I | By Spouse |
| Common Stock |  |  |  |  |  |  |  | 10199776<sup>(2)</sup> | I | By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee |
| Common Stock |  |  |  |  |  |  |  | 25457666<sup>(2)</sup> | I | By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee |
| Common Stock |  |  |  |  |  |  |  | 50000<sup>(2)</sup> | I | Immediate family member |
| Common Stock |  |  |  |  |  |  |  | 31000 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $2.64 | 2025-05-30 |  | M<sup>(1)</sup> |  |  | 74545 | <sup>(3)</sup> | 2034-01-02 | Common Stock | 74545 | $0 | 0<sup>(2)</sup> | I | By Spouse |

---

### Footnotes:

(1) On May 30, 2025, the Reporting Person's spouse exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of $2.64 per share. The Reporting Person's spouse did not sell the underlying shares.

(2) The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

(3) The option was granted on January 2, 2024. The shares underlying the option vested in four equal quarterly installments on March 31, June 30, September 30 and December 31, 2024.

**Signature:** /s/ Mahkam Zanganeh  
**Date:** 2025-06-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**